The rate of neoadjuvant chemotherapy use in muscle invasive bladder cancer and the approach of urologists in Turkey

Simple item page
dc.contributor.authorUcer O.
dc.contributor.authorAlbaz A.C.
dc.contributor.authorAtağ E.
dc.contributor.authorKaraoğlu A.
dc.contributor.authorMuezzinoglu T.
dc.date.accessioned2024-07-22T08:12:24Z
dc.date.available2024-07-22T08:12:24Z
dc.date.issued2016
dc.description.abstractPurpose: To investigate the proportion of neoadjuvant chemotherapy (NAC) use in patients with muscle invasive bladder cancer before radical cystectomy and the approach of urologists to this subject. Materials and Methods: We invited 242 urologists during the 12th International Urooncology Congress in Turkey to answer a self-administered questionnaire. The questionnaire included questions related to radical cystectomy, lymph node dissection and neoadjuvant chemotherapy that had been performed in patients with muscle invasive bladder cancer by the urologist. Results: The median number of radical cystectomy operations was 20 per year. 122 (50.5 %) of 242 urologists had used neoadjuvant chemotherapy for the treatment of muscle invasive bladder cancer before radical cystectomy. The mean rate of neoadjuvant chemotherapy use by these urologists (n=122) was 28.46 %. The most common reasons for not using neoadjuvant chemotherapy by urologists in Turkey were as follows: (i) neoadjuvant chemotherapy might lead to a decrease in the cure rate of radical cystectomy due to delayed surgery (ii) complication rate of radical cystectomy might be elevated and the surgery might be complicated by NAC use. Conclusion: Although the European Association of Urology (EAU) guidelines panel on muscle invasive bladder cancer recommends using NAC in T2-T4a bladder, the rate of neoadjuvant chemotherapy use was still found to be low in our country because urologists have concerns about adverse effects NAC on radical cystectomy.
dc.identifier.issn17351308
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16044
dc.language.isoEnglish
dc.publisherUrology and Nephrology Research Centre
dc.subjectAdult
dc.subjectChemotherapy, Adjuvant
dc.subjectCystectomy
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectMuscle, Smooth
dc.subjectNeoadjuvant Therapy
dc.subjectNeoplasm Invasiveness
dc.subjectPractice Patterns, Physicians'
dc.subjectTurkey
dc.subjectUrinary Bladder Neoplasms
dc.subjectUrology
dc.subjectYoung Adult
dc.subjectadjuvant chemotherapy
dc.subjectadult
dc.subjectclinical practice
dc.subjectcystectomy
dc.subjecthuman
dc.subjectmiddle aged
dc.subjectneoadjuvant therapy
dc.subjectpathology
dc.subjectsmooth muscle
dc.subjectstatistics and numerical data
dc.subjecttumor invasion
dc.subjectTurkey
dc.subjectUrinary Bladder Neoplasms
dc.subjecturology
dc.subjectyoung adult
dc.titleThe rate of neoadjuvant chemotherapy use in muscle invasive bladder cancer and the approach of urologists in Turkey
dc.typeArticle

Files

Collections

Scopus Koleksiyonu